InspireMD (NYSE:NSPR) Stock Price Down 1.8% – Should You Sell?

InspireMD, Inc. (NYSE:NSPR)’s stock price traded down 1.8% during trading on Thursday . The company traded as low as $1.6001 and last traded at $1.62. 17,462 shares traded hands during trading, a decline of 52% from the average session volume of 36,529 shares. The stock had previously closed at $1.65.

InspireMD Stock Down 1.8%

The business has a 50-day moving average price of $1.84 and a 200-day moving average price of $2.17. The firm has a market capitalization of $68.64 million, a price-to-earnings ratio of -2.16 and a beta of 0.72.

Hedge Funds Weigh In On InspireMD

Hedge funds have recently modified their holdings of the stock. Creative Planning acquired a new stake in InspireMD in the 2nd quarter worth approximately $44,000. Uniting Wealth Partners LLC acquired a new stake in shares of InspireMD during the third quarter worth $51,000. Citadel Advisors LLC grew its holdings in shares of InspireMD by 45.0% during the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock valued at $91,000 after buying an additional 11,778 shares during the last quarter. Raymond James Financial Inc. increased its position in shares of InspireMD by 28.9% in the 2nd quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after acquiring an additional 10,000 shares during the period. Finally, Vestia Personal Wealth Advisors lifted its position in InspireMD by 135.7% during the 3rd quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock worth $102,000 after acquiring an additional 24,425 shares during the period. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.